Search

Your search keyword '"Manconi, Pe"' showing total 157 results

Search Constraints

Start Over You searched for: Author "Manconi, Pe" Remove constraint Author: "Manconi, Pe"
157 results on '"Manconi, Pe"'

Search Results

1. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

2. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART

3. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

4. Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity

5. Incidence of Malignancies in HIV‐Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study

6. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

7. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study

8. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

9. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

10. Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008

11. Role of Microbial Translocation (MT) and Immune Hyperactivation (IH) in Liver Disease Progression of HIV/HCV plus Patients with well documented HIV seroconversion date and preserved CD4 count

12. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

13. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

14. Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women: Data From the ICONA Foundation Study Group, Years 1997-2013

15. The salivary proteome profile in patients affected by SAPHO syndrome characterized by a top-down RP-HPLC-ESI-MS platform

16. Limited occurrence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study

17. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy

18. Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction

19. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

20. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort

21. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count

22. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure

23. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

24. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study

25. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients

26. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

27. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures

28. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

29. ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI

30. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis

31. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

32. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

33. Genetic polymorphisms differently influencing the emergence of atrophy and fataccumulation in HIV-related lipodystrophy

34. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

35. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

36. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

37. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis

38. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?

41. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.

42. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

43. Evolution of HVR-1 Quasispecies after 1-Year Treatment in HIV/HCV-Coinfected Patients According to the Pattern of Response to Highly Active Antiretroviral Therapy

44. Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

45. The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

46. Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

47. Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart

48. Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

49. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

50. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

Catalog

Books, media, physical & digital resources